Cargando…
Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVID‐19 patients
BACKGROUND: Coronavirus disease‐2019 (COVID‐19) has been associated with cutaneous findings, some being the result of drug hypersensitivity reactions such as maculopapular drug rashes (MDR). The aim of this study was to investigate whether COVID‐19 may impact the development of the MDR. METHODS: Blo...
Autores principales: | Mitamura, Yasutaka, Schulz, Daniel, Oro, Saskia, Li, Nick, Kolm, Isabel, Lang, Claudia, Ziadlou, Reihane, Tan, Ge, Bodenmiller, Bernd, Steiger, Peter, Marzano, Angelo, de Prost, Nicolas, Caudin, Olivier, Levesque, Mitchell, Stoffel, Corinne, Schmid‐Grendelmeier, Peter, Maverakis, Emanual, Akdis, Cezmi A., Brüggen, Marie‐Charlotte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441838/ https://www.ncbi.nlm.nih.gov/pubmed/34157151 http://dx.doi.org/10.1111/all.14983 |
Ejemplares similares
-
011 Systemic hyperinflammation as a driver of maculopapular drug exanthema in severely ill COVID-19 patients?
por: Mitamura, Y., et al.
Publicado: (2021) -
Maculopapular Exanthema After the Second Dose of Evolocumab
por: Ghernautan, Victoria, et al.
Publicado: (2021) -
Benralizumab for severe DRESS in two COVID-19 patients
por: Schmid-Grendelmeier, Peter, et al.
Publicado: (2021) -
Cytotoxic diagnostic assays are effective in drug-induced maculopapular exanthemas
por: Porebski, Grzegorz, et al.
Publicado: (2015) -
HLA Risk Alleles in Aromatic Antiepileptic Drug-Induced Maculopapular Exanthema
por: Shi, Yi-Wu, et al.
Publicado: (2021)